175 related articles for article (PubMed ID: 15001334)
1. Ximelagatran or warfarin in atrial fibrillation?
Eikelboom J; Hankey G
Lancet; 2004 Feb; 363(9410):734; author reply 734, 736. PubMed ID: 15001334
[No Abstract] [Full Text] [Related]
2. Ximelagatran or warfarin in atrial fibrillation?
MacAllister R; Hingorani AD; Casas JP
Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
[No Abstract] [Full Text] [Related]
3. Ximelagatran or warfarin in atrial fibrillation?
Stöllberger C; Finsterer J
Lancet; 2004 Feb; 363(9410):734-5; author reply 736. PubMed ID: 15001336
[No Abstract] [Full Text] [Related]
4. Ximelagatran or warfarin in atrial fibrillation?
Epstein EF
Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
[No Abstract] [Full Text] [Related]
5. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
6. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
Kulbertus H
Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
[TBL] [Abstract][Full Text] [Related]
7. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
8. Can we pull the plug on warfarin in atrial fibrillation?
Verheugt FW
Lancet; 2003 Nov; 362(9397):1686-7. PubMed ID: 14643112
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of ximelagatran for stroke prevention.
Perret-Guillaume C; Wahl D
JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626
[No Abstract] [Full Text] [Related]
10. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
Halperin JL;
Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
[TBL] [Abstract][Full Text] [Related]
11. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Olsson SB;
Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
[TBL] [Abstract][Full Text] [Related]
12. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
[TBL] [Abstract][Full Text] [Related]
13. Ximelagatran compared with warfarin for the prevention of systemic embolism and stroke. An imputed placebo analysis.
Berry C; Norrie J; McMurray JJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):149-51. PubMed ID: 16025234
[TBL] [Abstract][Full Text] [Related]
14. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
15. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
16. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Cavuşoğlu Y
Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
[No Abstract] [Full Text] [Related]
17. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
Halperin JL
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
19. Ximelagatran--promises and concerns.
Gurewich V
JAMA; 2005 Feb; 293(6):736-9. PubMed ID: 15701916
[No Abstract] [Full Text] [Related]
20. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]